AbCellera rises 9% after hours as beneficiary of COVID antibody cocktail EUA expansion
Dec. 03, 2021 4:40 PM ETAbCellera Biologics Inc. (ABCL)LLYBy: Jonathan Block, SA News Editor4 Comments
- Shares of AbCellera Biologics (NASDAQ:ABCL) are up 9% in post-market trading, apparently getting a boost from the FDA Emergency Use Authorization expansion earlier in the day for bamlanivimab and etesevimab, developed with Eli Lilly (NYSE:LLY), for COVID-19.
- The EUA for the antibody cocktail was expanded to include children under the age of 12.
- Check out AbCellera's Q3 2021 earnings.